Ronen Arbel

1.5k total citations · 3 hit papers
53 papers, 832 citations indexed

About

Ronen Arbel is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Ronen Arbel has authored 53 papers receiving a total of 832 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Endocrinology, Diabetes and Metabolism, 16 papers in Cardiology and Cardiovascular Medicine and 14 papers in Surgery. Recurrent topics in Ronen Arbel's work include Diabetes Treatment and Management (19 papers), SARS-CoV-2 and COVID-19 Research (10 papers) and Pancreatic function and diabetes (8 papers). Ronen Arbel is often cited by papers focused on Diabetes Treatment and Management (19 papers), SARS-CoV-2 and COVID-19 Research (10 papers) and Pancreatic function and diabetes (8 papers). Ronen Arbel collaborates with scholars based in Israel, United States and United Kingdom. Ronen Arbel's co-authors include Ariel Hammerman, Ruslan Sergienko, Doron Netzer, Shlomit Yaron, Alon Peretz, Michael Friger, Erez Battat, Joseph Azuri, Yael Wolff Sagy and Gil Lavie and has published in prestigious journals such as New England Journal of Medicine, Circulation and Nature Medicine.

In The Last Decade

Ronen Arbel

47 papers receiving 815 citations

Hit Papers

Nirmatrelvir Use and Severe Covid-19 Outcomes during the ... 2022 2026 2023 2024 2022 2023 2023 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge
    2022 197 citations Ronen Arbel, Yael Wolff Sagy et al. profile →
  2. Real-world effectiveness of a single dose of mpox vaccine in males
    2023 119 citations Yael Wolff Sagy, Ariel Hammerman et al. Nature Medicine profile →
  3. Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study
    2023 86 citations Ronen Arbel, Ruslan Sergienko et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ronen Arbel Israel 12 382 176 159 144 121 53 832
Yatir Ben‐Shlomo Israel 6 677 1.8× 157 0.9× 131 0.8× 207 1.4× 9 0.1× 9 1.1k
Erez Battat Israel 11 187 0.5× 134 0.8× 169 1.1× 38 0.3× 116 1.0× 24 736
Eran Kopel Israel 17 264 0.7× 75 0.4× 200 1.3× 409 2.8× 15 0.1× 49 938
Gil Lavie Israel 10 233 0.6× 141 0.8× 118 0.7× 23 0.2× 120 1.0× 29 512
Yael Wolff Sagy Israel 9 183 0.5× 134 0.8× 130 0.8× 26 0.2× 110 0.9× 19 696
Angela Ishak United States 14 106 0.3× 75 0.4× 101 0.6× 88 0.6× 22 0.2× 47 458
Joseph Magagnoli United States 12 481 1.3× 106 0.6× 148 0.9× 46 0.3× 54 0.4× 47 794
Marianna Traugott Austria 13 561 1.5× 117 0.7× 85 0.5× 46 0.3× 12 0.1× 37 797
Sergio Reus Spain 14 253 0.7× 26 0.1× 291 1.8× 32 0.2× 124 1.0× 64 633
Paola Meraviglia Italy 19 941 2.5× 58 0.3× 368 2.3× 12 0.1× 556 4.6× 61 1.3k

Countries citing papers authored by Ronen Arbel

Since Specialization
Citations

This map shows the geographic impact of Ronen Arbel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronen Arbel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronen Arbel more than expected).

Fields of papers citing papers by Ronen Arbel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronen Arbel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronen Arbel. The network helps show where Ronen Arbel may publish in the future.

Co-authorship network of co-authors of Ronen Arbel

This figure shows the co-authorship network connecting the top 25 collaborators of Ronen Arbel. A scholar is included among the top collaborators of Ronen Arbel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronen Arbel. Ronen Arbel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sagy, Yael Wolff, Erez Battat, Ronen Arbel, et al.. (2025). Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer: an observational, retrospective cohort study. EClinicalMedicine. 83. 103213–103213. 3 indexed citations
2.
Sagy, Yael Wolff, et al.. (2025). Primary healthcare delivery adaptations in war-induced population displacement. Israel Journal of Health Policy Research. 14(1). 35–35.
3.
4.
Shani, Michal, Ilan Feldhamer, Orna Reges, et al.. (2024). The association between BNT162b2 vaccinations and incidence of immune-mediated comorbidities. Vaccine. 42(18). 3830–3837. 1 indexed citations
5.
Sagy, Yael Wolff, et al.. (2024). Effectiveness of bariatric metabolic surgery versus glucagon-like peptide-1 receptor agonists for prevention of congestive heart failure. Nature Medicine. 30(8). 2337–2342. 7 indexed citations
6.
Arbel, Ronen, et al.. (2024). Effectiveness and safety of molnupiravir in the intended-use population: an observational cohort study. Clinical Microbiology and Infection. 30(10). 1305–1311. 1 indexed citations
7.
Nadarajah, Ramesh, Jianhua Wu, David Hogg, et al.. (2023). Prediction of short-term atrial fibrillation risk using primary care electronic health records. Heart. 109(14). 1072–1079. 28 indexed citations
8.
Azuri, Joseph, et al.. (2023). Liraglutide versus semaglutide for weight reduction—a cost needed to treat analysis. Obesity. 31(6). 1510–1513. 17 indexed citations
9.
Raviv, Yuval, et al.. (2023). Examining the Patterns of Mpox Vaccine Uptake in a Vulnerable Population. Sexually Transmitted Diseases. 50(10). 680–684. 5 indexed citations
10.
11.
Tsaban, Gal, Adam Solomon, Jean Marc Weinstein, et al.. (2023). Effect of Dapagliflozin Versus Empagliflozin on Cardiovascular Death in Patients with Heart Failure Across the Spectrum of Ejection Fraction: Cost per Outcome Analysis. American Journal of Cardiovascular Drugs. 23(3). 323–328. 3 indexed citations
12.
Azuri, Joseph, et al.. (2022). Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis. Diabetes Obesity and Metabolism. 25(4). 961–964. 27 indexed citations
13.
Hammerman, Ariel, et al.. (2022). Oral versus subcutaneous semaglutide for prevention of major adverse cardiovascular events: cost per outcome analysis of SUSTAIN-6 and PIONEER-6. Postgraduate Medicine. 134(7). 654–658. 1 indexed citations
14.
Hammerman, Ariel, et al.. (2022). Usefulness of Empagliflozin Versus Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus. The American Journal of Cardiology. 170. 128–131. 2 indexed citations
15.
16.
Arbel, Ronen, et al.. (2021). Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia: Value for Money Analysis. The American Journal of Medicine. 134(7). e415–e419. 8 indexed citations
17.
18.
Arbel, Ronen, Candace Moore, Ruslan Sergienko, & Joseph S. Pliskin. (2021). How many lives do COVID vaccines save? Evidence from Israel. American Journal of Infection Control. 50(3). 258–261. 6 indexed citations
19.
Arbel, Ronen, et al.. (2021). Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus. The American Journal of Cardiology. 150. 65–68. 4 indexed citations
20.
Arbel, Ronen, Ariel Hammerman, & Joseph Azuri. (2019). Usefulness of Ezetimibe Versus Evolocumab as Add-On Therapy for Secondary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. The American Journal of Cardiology. 123(8). 1273–1276. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yatir Ben‐Shlomo Breakdown of academic impact, for papers by Erez Battat Breakdown of academic impact, for papers by Eran Kopel Breakdown of academic impact, for papers by Gil Lavie Breakdown of academic impact, for papers by Yael Wolff Sagy Breakdown of academic impact, for papers by Angela Ishak Breakdown of academic impact, for papers by Joseph Magagnoli Breakdown of academic impact, for papers by Marianna Traugott Breakdown of academic impact, for papers by Sergio Reus Breakdown of academic impact, for papers by Paola Meraviglia
Rankless by CCL
2026